TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of Patients achieving 50% or greater reduction in wound size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Conjunctival Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective postoperative recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite of major adverse events at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Hospitalizations for valve-related symptoms or worsening congestive heart failure
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Balance function evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4 week continuous quit rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skeletal muscle synthetic and breakdown rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hot and Cold Thermal Sensory Threshold for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical Pain Threshold for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suprathreshold Magnitude for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: baseline-adjusted LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Evaluator's global assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vaginal delivery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Vaginal delivery within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diagnostic performance of AMC and SWE elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum calcium profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Warming Sensation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Episodes of Influenza and Influenza-Like-Illness
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Seroprotected at Timepoint 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Montgomery-Asberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants Reporting Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With RVNA Concentrations >= 0.5 IU/mL, 7 Days After Booster Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient-reported risk factors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-reported feedback on Risk Assessment, Counselling, and Resources
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient-reported health behaviour change and motivation for health behaviour change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: DCI-IPG Measurements in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: DCI-IPG Measurements in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: oxidative lesion biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enrolment rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Client Satisfaction Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients with complete or partial recanalization of portal vein thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: AUC0-T of sildenafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in markers of endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in arterial stiffness with vitamin D3 supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Scapular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of Progression Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Median Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Radiographic Success as a Measure of Radiolucency and Component Migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Harris Hip Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction clinical assessment utilizing questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients responding to mailings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of individuals vaccinated with two doses of oral cholera vaccine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decrease number of cholera cases in intervention arm compared to non-intervention arm
Endpoint domain: Mortality/survival
Primary endpoint: Increase in serum creatinine (SCr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Illegal drug use
Endpoint domain: Adverse events/effects
Primary endpoint: Rearrest
Endpoint domain: Adverse events/effects
Primary endpoint: Probation Appointment Compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: toxicity of an intensive regimen
Endpoint domain: Adverse events/effects
Primary endpoint: toxicity of a single high dose of melphalan
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Episodes due to respiratory tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Episodes due to gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Wound improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Best Overall Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SAbR effects on cGAMP in tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SAbR effects on interferon response in tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SAbR effects on phosphor-STING in tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in Symptom Severity Scale (SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of coughing during emergence from general anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survivin status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clot Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clot Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Urinary concentration of Leucotriene E4 (LTE4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relief of irritable bowel syndrome symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Knee Extension test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Position Sense test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Motion Sense test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients and health-care workers presenting influenza illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in semantic encoding strategy use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: clinically significant improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: implant dose coverage at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sigmoidoscopy score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AMH cutoff value for ovarian response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Gait Symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in nycthemeral blood pressure profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LDL-c cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of fetal typing for RhD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (AUC, Cmax, Tmax, half life)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time from surgery to passage of gas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time from surgery to defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Linear Wear Rate at 5 Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Incidence of Revision of Component for Any Reason
Endpoint domain: Adverse events/effects
Primary endpoint: Dopamine turnover rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Impact of Event Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sVCAM 1 soluble Vascular Cell Adhesion Molecule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-hour Heart Rate Variability (HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Montreal Children's Hospital Feeding Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 2-Hour C-peptide Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Inhibition of Serum Thromboxane B2 (TXB2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tumor Necrosis Factor-Alpha (TNF-alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin-10 (IL-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: C-Reactive Protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return To Room Air (RTRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative Wound Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Inferior Corneal Fluorescein Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gingival Index (GI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of asymptomatic infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of drug resistance molecular markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in self-reported caffeine use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: bone-to-implant contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety and tolerability parameters including adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum observed plasma drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum observed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: capillary glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fasting blood sugar measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2 hours post prandial blood sugar measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analog scale for low back pain and leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants With Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants With Cognitive Impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Participants With Anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disabling and non-disabling stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Healing Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Changes After ACS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma and pharyngeal fluid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Timing and intensity of oral pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of action of polyvinylpyrrolidone-sodium hyaluronate gel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability, effectiveness, and adherence to regimens including polyvinylpyrrolidone-sodium hyaluronate gel
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to blood pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Syphilis Tests Undertaken
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Antibiotic sensitivity of detected organisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Disability of arm, shoulder and hand score (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tracer accumulation in tumor tissue vs normal pancreatic tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal dose of Bevacizumab-800CW for intraoperative imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supraspinatus pressure pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Arm Vascular Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Leg Vascular Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pharmacokinetics of atazanavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Knowledge and skills in illness self-management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Patient Activation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Acute Hospital Events
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Danger Assessment Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall number of participants with treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Immunoscore of the tumor microenvironment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in reversible perfusion defect size (RPDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with acute renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in average monthly migraine episode rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change From Baseline in Jebsen Taylor Hand Function Test Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Identified with Amyloidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative chronic pain scores (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time-Weighted Average (TWA) Percent Change From Baseline (CFB) in Morning FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Mean Maximum Jackson Cold Symptom Score (CSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration time curve in blood plasma after a single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Concentration (Cmax) after a single dose in blood plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration time curve in cervicovaginal fluid after a single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: decrease in serum CTX-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Grade 3 or Grade 4 Infusion Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Persistent medical morbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probing Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Best Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharyngeal Phase Dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appearance of grade II pressure ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in inflammatory markers or hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the circulating concentration versus time curve (AUC) of inflammatory markers or hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in intestinal epithelial damage and permeability markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area under the circulating concentration versus time curve (AUC) of intestinal epithelial damage and permeability markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in exercise induced endotoxaemia markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Length of stay after VATS lobectomy
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Presence of Ventilator-Associated-Pneumonia (VAP)
Endpoint domain: Mortality/survival
Primary endpoint: Prevention of acute chest syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tumor regression grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serology (IgM, IgG) for COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual analogue scale (VAS) of sciatic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Fatigue as Measured by the Brief Fatigue Inventory (BFI)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cross-sectional area of trunk muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: calprotectin in stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Levels of TNF Alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Gastric Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recovery time of clinical features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of plasma 25OHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of parathyroid hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes